EP 32: AI Discovers Drugs: The 2026 Clinical Trial Moment for AI in Biotech

Episode 4

0:00-7:56

For years, AI in drug discovery has been a promise—billions invested, hundreds of papers published, dozens of startups founded, but actual drugs coming out the other end? Not yet. This is changing in 2026. Several AI-discovered drug candidates are now entering mid-to-late stage clinical trials. This is the year the receipts arrive for AI in drug discovery. The biotech industry is calling 2026 a landmark year. For a sector that's been hyped as much as it's been scrutinized, the fact that we're finally getting real clinical data on AI-designed drug candidates is a big deal. Multiple candidates discovered and optimized using AI systems are now in Phase 2 and Phase 3 clinical trials, primarily focused on oncology and rare diseases—areas where existing options are limited and financial incentives for innovation are high. Companies furthest along include Insilico Medicine, Recursion Pharmaceuticals, and Exscientia. Their drug candidates were identified by AI systems analyzing massive biological datasets and predicting molecular structures likely to interact with disease targets in useful ways. What used to take teams of medicinal chemists years to accomplish, these systems can explore in weeks—a massive boost for clinical trial phases by reducing R&D time. Why this matters: Traditional drug discovery takes 10-15 years and over $1 billion per approved drug. Most candidates fail—the attrition rate in clinical trials is brutal.

Publisher

Data Science With Sam

Link

b230f277-a1c8-4919-9022-8b641676fe70.libsyn.com/ep-32-ai-discovers-drugs-the-2026-clinical-trial-moment-for-ai-in-biotech

Published

March 16, 2026

Duration

8 min

Format

Podcast

Category

Issues · Entrepreneurship

Source

RSS feed

Host

Soumava Dey

DS

Data Science With Sam

@datasciencewithsam

#aidiscoversdrugs #clinicaltrialmoment #biotech #entrepreneurship

The Nile